Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families.

Chen JY, Brockmöller J, Tzvetkov MV, Wang LJ, Chen XJ.

Chin J Nat Med. 2019 Jul;17(7):490-497. doi: 10.1016/S1875-5364(19)30070-6.

PMID:
31514980
2.

The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

J Neural Transm (Vienna). 2019 Jan;126(1):35-45. doi: 10.1007/s00702-018-01966-x. Epub 2019 Jan 4.

PMID:
30610379
3.

Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1).

Bokelmann K, Brockmöller J, Tzvetkov MV.

J Pers Med. 2018 Dec 11;8(4). pii: E42. doi: 10.3390/jpm8040042.

4.

OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil.

Matthaei J, Seitz T, Jensen O, Tann A, Prukop T, Tadjerpisheh S, Brockmöller J, Tzvetkov MV.

Clin Pharmacol Ther. 2019 Jan;105(1):190-200. doi: 10.1002/cpt.1128. Epub 2018 Aug 1.

PMID:
29882324
5.

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

Front Psychiatry. 2018 Mar 6;9:65. doi: 10.3389/fpsyt.2018.00065. eCollection 2018.

6.

Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age- vs. Genotype-Related Differences.

Dücker CM, Brockmöller J.

Clin Pharmacol Ther. 2019 Mar;105(3):625-640. doi: 10.1002/cpt.1057. Epub 2018 Apr 2. Review.

7.

Population nutrikinetics of green tea extract.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC.

PLoS One. 2018 Feb 21;13(2):e0193074. doi: 10.1371/journal.pone.0193074. eCollection 2018.

8.

Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.

Meyer MJ, Seitz T, Brockmöller J, Tzvetkov MV.

PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017.

9.

Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.

Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmöller J.

Clin Pharmacol Ther. 2018 May;103(5):868-878. doi: 10.1002/cpt.812. Epub 2017 Dec 8.

PMID:
28791698
10.

Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.

Just KS, Schneider KL, Schurig M, Stingl JC, Brockmöller J.

Pharmacogenomics. 2017 Aug;18(13):1281-1297. doi: 10.2217/pgs-2017-0018. Epub 2017 Aug 4. Review.

PMID:
28776468
11.

Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines.

Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W.

Clin Neurophysiol. 2017 Sep;128(9):1774-1809. doi: 10.1016/j.clinph.2017.06.001. Epub 2017 Jun 19. Review.

12.

Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study.

Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M.

PLoS Med. 2017 Apr 25;14(4):e1002286. doi: 10.1371/journal.pmed.1002286. eCollection 2017 Apr.

13.

Pharmacogenomic aspects of bipolar disorder: An update.

Budde M, Degner D, Brockmöller J, Schulze TG.

Eur Neuropsychopharmacol. 2017 Jun;27(6):599-609. doi: 10.1016/j.euroneuro.2017.02.001. Epub 2017 Mar 23. Review.

14.

Erratum to: Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families.

Chen J, Brockmöller J, Seitz T, König J, Tzvetkov MV, Chen X.

Biol Chem. 2017 Jun 27;398(7):813. doi: 10.1515/hsz-2017-0129. No abstract available.

PMID:
28291733
15.

Multimorbidity, polypharmacy and pharmacogenomics in old age.

Brockmöller J, Stingl JC.

Pharmacogenomics. 2017 Apr;18(6):515-517. doi: 10.2217/pgs-2017-0026. Epub 2017 Mar 14. No abstract available.

16.

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.

Matthaei J, Tzvetkov MV, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg JB, Hofmann U, Schwab M, Kerb R, Brockmöller J.

Genome Med. 2016 Nov 8;8(1):119.

17.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2016 Nov 1;6(11):e937. doi: 10.1038/tp.2016.187. No abstract available.

18.

Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.

Stamer UM, Musshoff F, Stüber F, Brockmöller J, Steffens M, Tzvetkov MV.

Pain. 2016 Nov;157(11):2467-2475.

PMID:
27541716
19.

Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families.

Chen J, Brockmöller J, Seitz T, König J, Chen X, Tzvetkov MV.

Biol Chem. 2017 Feb 1;398(2):237-249. doi: 10.1515/hsz-2016-0236. Erratum in: Biol Chem. 2017 Jun 27;398(7):813.

PMID:
27676604
20.

Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2.

Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R, Brockmöller J.

Clin Pharmacol Ther. 2016 Dec;100(6):606-616. doi: 10.1002/cpt.444. Epub 2016 Sep 23.

PMID:
27509179
21.

Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

Schirmer MA, Lüske CM, Roppel S, Schaudinn A, Zimmer C, Pflüger R, Haubrock M, Rapp J, Güngör C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmöller J, Ghadimi BM.

J Natl Cancer Inst. 2016 Feb 8;108(5). doi: 10.1093/jnci/djv387. Print 2016 May.

22.

[Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Stingl JC, Just KS, Kaumanns K, Schurig-Urbaniak M, Scholl C, von Mallek D, Brockmöller J.

Internist (Berl). 2016 Mar;57(3):289-97. doi: 10.1007/s00108-015-0013-7. Review. German.

PMID:
26830424
23.

OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics.

Matthaei J, Kuron D, Faltraco F, Knoch T, Dos Santos Pereira JN, Abu Abed M, Prukop T, Brockmöller J, Tzvetkov MV.

Clin Pharmacol Ther. 2016 Jun;99(6):633-41. doi: 10.1002/cpt.317. Epub 2016 Jan 12.

PMID:
26659468
24.

High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.

Hasheminasab SM, Tzvetkov MV, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Brockmöller J, Stingl JC.

Pharmacogenomics. 2015;16(14):1605-19. doi: 10.2217/pgs.15.97. Epub 2015 Sep 30.

PMID:
26419366
25.

Heritability of metoprolol and torsemide pharmacokinetics.

Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R.

Clin Pharmacol Ther. 2015 Dec;98(6):611-21. doi: 10.1002/cpt.258. Epub 2015 Oct 19.

PMID:
26344676
26.

Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.

Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira JN, Krätzner R, Brockmöller J, Tzvetkov MV.

Genome Med. 2015 Jun 18;7(1):56. doi: 10.1186/s13073-015-0172-0. eCollection 2015.

27.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2015 Apr 21;5:e553. doi: 10.1038/tp.2015.47. Erratum in: Transl Psychiatry. 2016 Nov 1;6(11):e937.

28.

Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.

Dalila N, Brockmöller J, Tzvetkov MV, Schirmer M, Haubrock M, Vormfelde SV.

Pharmacogenomics. 2015 Jan;16(2):115-27. doi: 10.2217/pgs.14.163.

PMID:
25616098
29.

The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA, Couraud PO, Brockmöller J, Tzvetkov MV.

AAPS J. 2014 Nov;16(6):1247-58. doi: 10.1208/s12248-014-9649-9. Epub 2014 Aug 26.

30.

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

Tzvetkov MV, Seitz T, Bokelmann K, Mueller T, Brockmöller J, Koepsell H.

Blood. 2014 Feb 27;123(9):1427-9. doi: 10.1182/blood-2013-11-535864. No abstract available.

31.

Genetic polymorphisms in 11β-hydroxysteroid dehydrogenase type 1 correlate with the postdexamethasone cortisol levels and bone mineral density in patients evaluated for osteoporosis.

Siggelkow H, Etmanski M, Bozkurt S, Groβ P, Koepp R, Brockmöller J, Tzvetkov MV.

J Clin Endocrinol Metab. 2014 Feb;99(2):E293-302. doi: 10.1210/jc.2013-1418. Epub 2013 Nov 27.

PMID:
24285685
32.

Polymorphic OCT1: a valid biomarker, but for which drugs?

Brockmöller J, Tzvetkov MV.

Pharmacogenomics. 2013 Dec;14(16):1933-6. doi: 10.2217/pgs.13.189. No abstract available.

PMID:
24279844
33.

[Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].

Stingl JC, Brockmöller J.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1509-21. doi: 10.1007/s00103-013-1822-2. Review. German.

PMID:
24170080
34.

Routine micromethod for the determination of vitamin K1 in human plasma.

Meineke I, Willnow C, Stingl J, Brockmöller J.

Ther Drug Monit. 2013 Dec;35(6):859-62. doi: 10.1097/FTD.0b013e31828eff38.

PMID:
24089072
35.

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J.

Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27. Review.

PMID:
24076267
36.

Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

O'Brien VP, Bokelmann K, Ramírez J, Jobst K, Ratain MJ, Brockmöller J, Tzvetkov MV.

J Pharmacol Exp Ther. 2013 Oct;347(1):181-92. doi: 10.1124/jpet.113.206359. Epub 2013 Aug 6.

37.

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J.

Biochem Pharmacol. 2013 Sep 1;86(5):666-78. doi: 10.1016/j.bcp.2013.06.019. Epub 2013 Jul 5.

38.

Halogenated volatile anesthetics alter brain metabolism as revealed by proton magnetic resonance spectroscopy of mice in vivo.

Boretius S, Tammer R, Michaelis T, Brockmöller J, Frahm J.

Neuroimage. 2013 Apr 1;69:244-55. doi: 10.1016/j.neuroimage.2012.12.020. Epub 2012 Dec 21.

PMID:
23266699
39.

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.

Stingl JC, Brockmöller J, Viviani R.

Mol Psychiatry. 2013 Mar;18(3):273-87. doi: 10.1038/mp.2012.42. Epub 2012 May 8. Review.

PMID:
22565785
40.

The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1.

Saadatmand AR, Tadjerpisheh S, Brockmöller J, Tzvetkov MV.

Biochem Pharmacol. 2012 May 15;83(10):1427-34. doi: 10.1016/j.bcp.2012.01.032. Epub 2012 Feb 10.

PMID:
22342776
41.

Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype.

Seegers J, Vos MA, Flevari P, Willems R, Sohns C, Vollmann D, Lüthje L, Kremastinos DT, Floré V, Meine M, Tuinenburg A, Myles RC, Simon D, Brockmöller J, Friede T, Hasenfuß G, Lehnart SE, Zabel M; EUTrigTreat Clinical Study Investigators.

Europace. 2012 Mar;14(3):416-22. doi: 10.1093/europace/eur352. Epub 2011 Nov 23.

42.

Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.

Schirmer MA, Mergler CP, Rave-Fränk M, Herrmann MK, Hennies S, Gaedcke J, Conradi LC, Jo P, Beissbarth T, Hess CF, Becker H, Ghadimi M, Brockmöller J, Christiansen H, Wolff HA.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):149-57. doi: 10.1016/j.ijrobp.2011.05.063. Epub 2011 Oct 12.

PMID:
22000747
43.

Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.

Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmöller J, Benöhr P.

Pharmacogenomics. 2011 Oct;12(10):1417-27. doi: 10.2217/pgs.11.93. Epub 2011 Sep 8.

PMID:
21902499
45.

Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

Parmar S, Stingl JC, Huber-Wechselberger A, Kainz A, Renner W, Langsenlehner U, Krippl P, Brockmöller J, Haschke-Becher E.

Breast Cancer Res. 2011 Jun 9;13(3):R57. doi: 10.1186/bcr2894.

46.

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmöller J.

Pharmacogenomics. 2011 Jun;12(6):783-95. doi: 10.2217/pgs.11.20. Epub 2011 May 23.

47.

Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.

Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J.

Clin Pharmacol Ther. 2011 Jul;90(1):143-50. doi: 10.1038/clpt.2011.56. Epub 2011 May 11.

PMID:
21562485
48.

Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.

Stingl Kirchheiner JC, Brockmöller J.

Clin Pharmacol Ther. 2011 Feb;89(2):198-209. doi: 10.1038/clpt.2010.274. Epub 2011 Jan 5. Review.

PMID:
21209614
49.

A putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a potential biomarker for radiosensitivity.

Schirmer MA, Brockmöller J, Rave-Fränk M, Virsik P, Wilken B, Kühnle E, Campean R, Hoffmann AO, Müller K, Goetze RG, Neumann M, Janke JH, Nasser F, Wolff HA, Ghadimi BM, Schmidberger H, Hess CF, Christiansen H, Hille A.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):866-74. doi: 10.1016/j.ijrobp.2010.08.040. Epub 2010 Dec 22.

PMID:
21183289
50.

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron.

Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J.

Pharmacogenomics J. 2012 Feb;12(1):22-9. doi: 10.1038/tpj.2010.75. Epub 2010 Oct 5.

PMID:
20921968

Supplemental Content

Loading ...
Support Center